Compare SNOA & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNOA | GLMD |
|---|---|---|
| Founded | 1999 | 2000 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0M | 4.0M |
| IPO Year | 2006 | 2013 |
| Metric | SNOA | GLMD |
|---|---|---|
| Price | $1.12 | $0.57 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 84.2K | ★ 305.4K |
| Earning Date | 06-16-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.26 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $19,529,000.00 | N/A |
| Revenue This Year | $23.00 | N/A |
| Revenue Next Year | $24.59 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 36.68 | N/A |
| 52 Week Low | $0.85 | $0.41 |
| 52 Week High | $6.92 | $2.34 |
| Indicator | SNOA | GLMD |
|---|---|---|
| Relative Strength Index (RSI) | 40.90 | 44.46 |
| Support Level | $1.02 | $0.53 |
| Resistance Level | $1.25 | $0.69 |
| Average True Range (ATR) | 0.08 | 0.08 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 30.43 | 56.17 |
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. The company focuses on the development of Aramchol for combination therapy for GI oncological indications. The company is actively pursuing opportunities in the biotech and medtech spaces to expand and diversify its product pipeline targeting GI, cardiometabolic indications and other product candidates.